| Item Type | Name |
|
Academic Article
|
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
|
|
Academic Article
|
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.
|
|
Concept
|
Melphalan
|
|
Academic Article
|
Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
|
|
Academic Article
|
Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma.
|
|
Academic Article
|
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.
|
|
Academic Article
|
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.
|
|
Academic Article
|
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.
|
|
Academic Article
|
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.
|
|
Academic Article
|
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.
|
|
Academic Article
|
Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.
|
|
Academic Article
|
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.
|
|
Academic Article
|
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
|
|
Academic Article
|
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
|
|
Academic Article
|
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
|
|
Academic Article
|
Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
|
|
Academic Article
|
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
|
|
Academic Article
|
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
|
|
Academic Article
|
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
|
|
Academic Article
|
Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma.
|
|
Academic Article
|
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
|
|
Academic Article
|
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.
|
|
Academic Article
|
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
|
|
Academic Article
|
Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.
|
|
Academic Article
|
Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma.
|
|
Academic Article
|
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.
|
|
Academic Article
|
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
|
|
Academic Article
|
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell?Transplantation for Relapsed and Refractory Hodgkin?Lymphoma.
|
|
Academic Article
|
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas
|
|
Academic Article
|
Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning
|
|
Academic Article
|
Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells
|
|
Academic Article
|
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
|
|
Academic Article
|
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.
|
|
Academic Article
|
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
|
|
Academic Article
|
Outcomes of Haploidentical Stem Cell Transplantation for?Lymphoma with Melphalan-Based Conditioning.
|
|
Academic Article
|
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
|
|
Academic Article
|
Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
|
|
Academic Article
|
Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.
|
|
Academic Article
|
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
|
|
Academic Article
|
Melphalan-based autologous transplant in octogenarian multiple myeloma patients.
|
|
Academic Article
|
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.
|
|
Academic Article
|
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.
|
|
Academic Article
|
Outcomes of autologous stem cell transplantation in Waldenstr?m's macroglobulinemia.
|
|
Academic Article
|
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation.
|
|
Academic Article
|
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
|
|
Academic Article
|
Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM.
|
|
Academic Article
|
Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma.
|
|
Academic Article
|
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
|